dose adjustments of these medications may be necessary [1] [3] Acute pancreatitis rare but serious
However, semaglutide has cardiovascular outcome data (the SELECT trial) that tirzepatide does not yet have from a completed dedicated outcomes trial
14,17 Pharmacists and clinicians should counsel patients on red-flag symptoms that require prompt evaluation, such as persistent or severe abdominal pain, intractable nausea or vomiting, abdominal distention, bloating lasting several days, or the presence of bloody stools
However, when patients were then presented with a video detailing the dosing conditions required with oral semaglutide and those with once-weekly injectable dulaglutide, 52.5% indicated a preference for oral semaglutide [90]
Different medications produce different degrees of gastric emptying delay, and individual responses vary significantly